Compare STHO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STHO | IMUX |
|---|---|---|
| Founded | 2022 | 2016 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.0M | 100.2M |
| IPO Year | 2022 | 2013 |
| Metric | STHO | IMUX |
|---|---|---|
| Price | $7.81 | $7.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $43.09 |
| AVG Volume (30 Days) | 38.8K | ★ 330.0K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.73 | ★ 38.00 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.01 | $0.51 |
| 52 Week High | $9.94 | $17.43 |
| Indicator | STHO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 42.34 |
| Support Level | $7.76 | $6.35 |
| Resistance Level | $8.20 | $8.60 |
| Average True Range (ATR) | 0.25 | 0.57 |
| MACD | 0.07 | 0.22 |
| Stochastic Oscillator | 50.59 | 61.97 |
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.